A Conversation with Doug Durand

I met Doug at Merck where he worked as a sales executive and I was an external consultant. Some years later, he called me from his current pharma company and asked my advice about an ethical issue he was seeing. About five years later, he was presented with a huge (listen to find out how much) “whistleblowers award” for turning the dangerous practices in for the government to investigate and eliminate. We talk here about the courage and risks of being a whistleblower (two such people formerly employed by Boeing have since died, one by suicide, one by unknown causes, and Doug faced physical threats) and why they are needed more than ever today. We discuss whether drug prices are reasonable in light of the investment in creating them and, if efficacious, obtaining FDA approval. The results might surprise you. We also discuss the high mortality diseases, such as Alzheimer’s, diabetes, and cancer, and whether too much is spent on “cure” and treatment at the expense of investment in prevention. The issue of extending life, but with quality, is raised, as is the need for certain types of surgery being abandoned. Also examined is the ironic serendipity of drug creation, aside from huge, targeted investment, which we’ve seen result in weight loss, hair growth, and the eradication of African River Blindness. Sometimes, even with drugs, it’s better to be lucky than good. And don’t miss our focus on opioids and the absence of whistleblowers among people who should have acted but didn’t throughout this crisis.

There are no comments yet.

Please log in to write the first comment.